IBTK

IBTK is a multifunctional adaptor protein that operates in two distinct regulatory regimes: negative control of B cell receptor signaling and positive control of cap-dependent translation (PMID:11577348, PMID:38738857). It was first defined as a trans-inhibitor of Bruton's tyrosine kinase, binding directly to the Btk PH domain and suppressing Btk kinase activity, calcium mobilization, and NF-κB-driven transcription (PMID:11577348). In a separate, later-defined role, IBTK serves as the substrate-recognition subunit of a Cullin 3-RING ubiquitin ligase (CRL3IBTK), recruiting eIF4A1 for non-degradative ubiquitination that enhances translational initiation and nascent protein synthesis; mTORC1 and S6K1 directly phosphorylate IBTK to amplify this activity and sustain oncogenic translation (PMID:38738857). In Myc-driven B cell contexts, IBTK sustains pre-cancerous B cell survival by limiting MCL-1- and p53-dependent apoptosis without affecting proliferation, and its expression is itself transcriptionally regulated by Myc (PMID:30975981). Consistent with this pro-survival role, IBTK loss shapes the lymphoma immunophenotype and microenvironment (PMID:32019112) and sensitizes lymphoma B cells to Rituximab-induced apoptosis with reduced MYC expression (PMID:38371626). The human locus is structurally complex, producing three protein isoforms from distinct promoters and a Dicer-processed intronic miRNA precursor (PMID:18596081, PMID:19782003).

1. 2001 High

   Established the founding molecular function of IBTK as a direct negative regulator of Btk, answering whether B cell signaling kinases are subject to dedicated trans-inhibitory partners.

   Evidence PH-domain binding assay, kinase activity assay, calcium mobilization, and NF-κB reporter readouts

   PMID:11577348

   Open questions at the time

   • Structural basis of the PH-domain interaction not resolved
   • In vivo physiological consequence of Btk inhibition not tested genetically
   • Did not address other IBTK functions later discovered
2. 2008 High

   Defined the architecture of the human IBTK locus, showing the gene produces three distinct protein isoforms and clarifying which products exist before functional studies could be attributed.

   Evidence Northern blot, 5'/3' RACE, and isoform-specific antibody detection in human cells and mouse tissues

   PMID:18596081

   Open questions at the time

   • Distinct functions of the three isoforms not assigned
   • Tissue- and context-specific isoform regulation not mapped
3. 2009 Medium

   Showed the IBTK locus encodes a non-coding regulatory output, identifying an intronic pre-miRNA processed by Dicer and broadening the locus beyond its protein products.

   Evidence Computational prediction, in vitro Dicer cleavage assay, and in vivo mature miRNA detection

   PMID:19782003

   Open questions at the time

   • Targets and physiological role of the mature miRNA not identified
   • Single-lab finding without mechanistic follow-up on the miRNA product
4. 2019 High

   Placed IBTK in the Myc oncogenic axis in vivo, answering whether IBTK contributes to B cell transformation by demonstrating it sustains pre-cancerous B cell survival rather than proliferation.

   Evidence Ibtk knockout x Eμ-myc mice with Annexin V, Caspase 3/7, cell cycle, ChIP-seq, and tet-repressible Myc readouts

   PMID:30975981

   Open questions at the time

   • Biochemical mechanism linking IBTK to MCL-1 and p53 not resolved
   • How Myc transcriptionally drives IBTK at the molecular level not detailed
5. 2020 Medium

   Extended IBTK's tumor role to the microenvironment, testing whether IBTK dosage influences lymphoma immunophenotype and angiogenesis.

   Evidence Ibtk hemizygous x Eμ-myc mice with immunophenotyping, angiogenic factor measurement, and macrophage quantification

   PMID:32019112

   Open questions at the time

   • Link between IBTK dosage and microenvironmental changes is correlative, not biochemically resolved
   • Mechanism of angiogenic factor induction unknown
6. 2024 High

   Revealed an entirely distinct enzymatic-adaptor function, answering how IBTK promotes oncogenic protein synthesis: as the CRL3 substrate adaptor that ubiquitinates eIF4A1 non-degradatively, with mTORC1/S6K1 phosphorylation as an upstream amplifier.

   Evidence Co-IP, reconstituted in vitro ubiquitination, in vitro kinase assay, polysome/nascent synthesis profiling, mutagenesis, and tumor xenografts

   PMID:38738857

   Open questions at the time

   • Ubiquitination sites and consequence for eIF4A1 conformation/activity not fully defined
   • Relationship between the CRL3 role and the Btk-inhibitory role not integrated
   • Phosphorylation sites on IBTK not exhaustively mapped
7. 2024 Medium

   Tested therapeutic relevance, showing IBTK silencing synergizes with Rituximab to drive lymphoma apoptosis and lowers MYC expression.

   Evidence siRNA knockdown with Annexin V, cell cycle analysis, transplanted Eμ-myc lymphoma model, and MYC expression analysis

   PMID:38371626

   Open questions at the time

   • Mechanistic connection between IBTK and MYC expression not biochemically resolved
   • Single-lab loss-of-function study

• How IBTK's two opposing roles — Btk inhibition versus CRL3-mediated promotion of translation — are coordinated within a single cell, and whether specific isoforms partition between them, remains unresolved.
• Isoform-to-function mapping not established
• No integrated model reconciling signaling-inhibitory and ubiquitin-ligase activities
• Structural data for IBTK absent